https://www.selleckchem.com/products/a-196.html Metastasis is responsible for 90% of colorectal cancer (CRC)-related deaths. In the present study, we identified a novel key regulator of CRC metastasis, leucine-rich repeats and immunoglobulin-like domains protein 3 (LRIG3), which was significantly decreased in CRC tissues and cell lines. Downregulation of LRIG3 was attributed to copy number loss and promoter hypermethylation. Low LRIG3 expression was positively correlated with metastatic clinical features and shorter survival time. Functional experiments showed that knockout of LRIG3 markedly enhanced CRC cell migration and invasion ability, whereas reintroduction of LRIG3 exerted the opposite effects. Regarding the mechanism, LRIG3 could facilitate the binding of DUSP6 to ERK1/2, resulting in the dephosphorylation of ERK1/2 and subsequently downregulation of slug, an epithelial-to-mesenchymal transition trigger, thereby constraining CRC cell motility. Importantly, LRIG3 expression was strongly negatively correlated with slug or p-ERK1/2 expression in CRC tissues. Collectively, our data suggest that LRIG3 is a novel suppressor of CRC metastasis, reactivation of LRIG3 may be a promising therapeutic approach for metastatic CRC patients. © 2020 International Union of Biochemistry and Molecular Biology.INTRODUCTION von Willebrand disease (VWD) diagnosis starts with first level tests factor VIII coagulant activity, VWF antigen (VWFAg) and platelet-dependent VWF activity (VWFRCo, VWFAb, VWFGPIbR or VWFGPIbM). The VWF collagen binding (VWFCB) assay measures the binding capacity of von Willebrand factor (VWF) to collagen. AIM To assess, in previously diagnosed VWD patients, the performance of a fully automated chemiluminescent test panel including VWFAg, VWFGPIbR and VWFCB assays. METHODS The patients, historically evaluated using in-house VWFAg and VWFCB assays and an automated latex enhanced immunoassay VWFGPIbR method, were re-evaluated using the VWF test panel HemosIL Ac